The aim of the 3rd RSC–BMCS Fragment-based Drug Discovery meeting will be to continue the focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late-stage medicinal chemistry, preclinical or clinical programmes. These case studies will include successful examples from all types of fragment-based approaches, including high concentration, ÐÂÔÂÖ±²¥appÏÂÔØ, SPR and X-ray screening.